secwatch.observer — SEC 8-K summary
======================================

Issuer:     Transcode Therapeutics, Inc. (RNAZ)
CIK:        0001829635
Form:       8-K
Filed at:   2026-07-20T20:15:27+00:00
Accession:  0001104659-26-085073
Event type: other_material
Sentiment:  neutral
Materiality: 0.15
Item codes: 5.07
LLM model:  deepseek-v4-flash:cloud@v2

TransCode shareholders approve preferred stock conversion, stock plan increase, and director elections
--------------------------------------------------------------------------------

- Approved conversion of Series A, B, and C preferred stock into common stock for Nasdaq listing compliance.
- Stockholders approved amendment to 2021 Stock Option Plan increasing available shares by 1,734,262.
- Elected six directors: Philippe P. Calais, Elizabeth Czerepak, Thomas A. Fitzgerald, Erik Manting, Magda Marquet, Jack E. Stover.
- Ratified WithumSmith+Brown, PC as independent auditor for FY 2026 with 393,497 votes for.
- Nasdaq approved the Company's initial listing application in connection with Proposals 1 and 2.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1829635/000110465926085073/0001104659-26-085073-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1829635/000110465926085073/tm2620898d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-085073

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer